| 영문 | muscle cell(=muscle fiber) | 한글 | 근육세포 |
|---|---|---|---|
| 설명 | 근육은 수의근(의식에 의해서 조절이 가능한 근육: 예를 들어 다리, 팔, 얼굴근육 등)과 불수의근(의식과 무관하게 조절하지 않아도 움직이는 근육: 예를 들어 심장근, 소화기관에 분포하는 근육 등)으로 나누어지며, 근육세포의 모양은 다음과 같다(수의근, 불수의근 외에 심장에 있는 심장근은 불수의근에 해당하지만 그 모양은 수의근과 같아 따로 분류한다).  |
||
| 영문 | antiglobulin antibody | 한글 | 항글로불린항체 |
|---|---|---|---|
| 설명 | 항체에 대한 항체, 즉 특정 항체와 결합할 수 있는 항체. 대개 인간의 항체를 쥐에 주사하여 쥐로 하여금 인간 항체에 대한 항체를 만들게 한다(쥐에 있어서는 인간의 항체도 외부에서 들어온 물질이므로). 이것은 여러 가지 실험에서 인간의 특정항체를 검출하는데 이용한다. |
||
| 영문 | antibody | 한글 | 항체 |
|---|---|---|---|
| 설명 | 사람의 몸에서 면역에 관계하는 물질. 외부에서 들어온 물질과 꼭 맞게 결합을 하여서 그 물질의 생물학적 활동을 억제하거나 파괴하거나 사람의 다른 면역세포로 하여금 공격하기 용이하게 해주는 기능을 가지고 있다. 항체는 면역글로부린이라는 것으로 이루어져 있고 그 형태에 따라 IgA, IgE, IgG, IgD등으로 나눈다. |
||
| 영문 | striated muscle | 한글 | 가로무늬근 |
|---|---|---|---|
| 설명 | 표면에 가로줄무늬가 보이는 근육. 뜻대로 움직일 수 있으므로 수의근이라고도 불린다. 인체의 가로무늬근의 대부분은 골격근이며, 얼굴의 피부를 움직이는 표정근, 혀나 후두를 움직이는 근육도 가로무늬근이다. 예를 들어 팔을 구부릴 때는 많은 근육의 복잡한 협조가 필요하여 전체적인 움직임을 통제하는 기구가 있다. 또 자세의 균형을 잡을 때 등 많은 운동을 무의식적-반사적으로 조절하는 기구도 있다. 심장근은 가로무늬근이지만 불수의근의 성질을 가졌다. |
||
| 영문 | skeletal muscle | 한글 | 골격근 |
|---|---|---|---|
| 설명 | 골격에 붙어 그 운동을 관장하는 근육계. 골격근-평활근-심장근 등 세 개 근조직의 하나. 굵기 10~100μ, 길이 5~12cm의 가늘고 긴 근육섬유의 집합체이며, 가로무늬가 있고, 수의운동을 한다. 한 개의 골격근은 다수의 근섬유와 결합조직으로 구성되고 각기 특유한 형태를 지닌다. 근육의 양끝은 가늘며 그 부분을 근육머리라고 한다. 근육머리는 힘줄로 이행하며 힘줄은 뼈막에 붙는데, 때로는 뼈막을 뚥고 뼈에 부착되어 있다. 근육의 중앙부는 굵고 두꺼우며 이부분을 근복이라 한다. 근육머리는 다시 두갈래근-세갈래근-네갈래근으로 나뉜다. 근육의 운동 자체는 항상 근섬유의 방향에 따르는 수축운동뿐이다. 그러나 골격근이 뼈에 붙은 위치에 따라 뼈대에 대한 여러 가지 운동을 하게 된다. 운동하는 형태로 골격근을 분류하면 폄근-굽힘근-내전근-외전근-회외근-회내근-올림근 등이 있다. 굽히고 폄-내외전-회내외의 운동은 관절축을 중심으로 행한다. 같은 골격에 대하여 펌근육과 굽힘근육이 각기 반대운동을 할 경우에는 양 근육을 서로 대항근이라 하고, 공동운동을 하는 경우에는 공동근이라 한다. |
||
| ASMA | antismooth muscle antibody |
|---|---|
| AMA | against medical advice; alkaline membrane assay; American Management Association; American Medical A... |
| ACA | abnormal coronary artery; acrodermatitis chronica atrophicans; acute cerebellar ataxia; adenocarcino... |
| MR | Maddox rods; magnetic resistance; magnetic resonance; mandibular reflex; mannose-resistant; may repe... |
| NA | Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida... |
| SMA | Smooth muscle antibody |
|---|---|
| ADM | Abductor digiti minimi muscle |
| ASM | Airway smooth muscle |
| alpha-SMA | Alpha smooth muscle actin |
| ASMA | Alpha-smooth muscle actin |
| affinity antibody | The measure of the interaction between molecules such as a receptor and its ligand. This interaction is reversible. (05 Mar 2000) |
|---|---|
| agglutinating antibody | 1. An antibody that causes clumping or agglutination of the bacteria or other cells which either stimulated the formation of the agglutinin, or contain immunologically similar, reactive antigen. Synonym: agglutinating antibody, immune agglutinin. 2. A substance, other than a specific agglutinating antibody, that causes organic particles to agglutinate, commonly qualified, e.g., plant agglutinin. (05 Mar 2000) |
| anaphylactic antibody | Antibody that has an affinity for certain kinds of cells, in addition to and unrelated to its specific affinity for the antigen that induced it, because of the properties of the Fc portion of the heavy chain. See: heterocytotropic antibody, homocytotropic antibody, cytotropic antibody test. Synonym: anaphylactic antibody, cytophilic antibody. (05 Mar 2000) |
| anti-basement membrane antibody | Autoantibodies to renal glomerular basement membrane antigens. (05 Mar 2000) |
| antibody | An immunoglobulin molecule that has a specific amino acid sequence by virtue of which it interacts only with the antigen that induced its synthesis in cells of the lymphoid series (especially plasma cells) or with antigen closely related to it. Antibodies are classified according to their ode of action as agglutinins, bacteriolysins, haemolysins, opsonins, precipitins, etc. (18 Nov 1997) |
| antibody affinity | A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. (12 Dec 1998) |
| antibody aldolase | <enzyme> Prepared by reactive immuninization to catalyze a wide variety of aldol reactions and decarboxylations Registry number: EC 4.1.2.- Synonym: fab 33f12, aldolase catalytic antibody (26 Jun 1999) |
| antibody-coated bacteria test, urinary | Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively. (12 Dec 1998) |
| antibody combining site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antibody deficiency disease | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody deficiency syndrome | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody-dependent cell cytotoxicity | The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. (12 Dec 1998) |
| antibody-dependent enhancement | Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors. (12 Dec 1998) |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |
| antibody diversity | The phenomenon of immense variability characteristic of antibodies, which enables the immune system to react specifically against the essentially unlimited kinds of antigens it encounters. Antibody diversity is accounted for by three main theories: 1) the germ line theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; 2) the somatic mutation theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and 3) the gene rearrangement theory, which holds that antibody diversity is generated by the rearrangement of variable region gene segments during the differentiation of the antibody-producing cells. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|